Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations.

IF 3.8 3区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Current opinion in lipidology Pub Date : 2024-08-01 Epub Date: 2024-03-27 DOI:10.1097/MOL.0000000000000935

Paulina Elena Stürzebecher, Ulrich Laufs

{"title":"Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations.","authors":"Paulina Elena Stürzebecher, Ulrich Laufs","doi":"10.1097/MOL.0000000000000935","DOIUrl":null,"url":null,"abstract":"Purpose of review: Monoclonal antibodies (mAb) targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) have been established in cardiovascular risk prevention. The purpose of this review is to summarize the effects of PCSK9 inhibitors across different patient populations.Recent findings: Long-term data on the use of evolocumab and alirocumab shows persisting low- density lipoprotein cholesterol (LDL-C) lowering and good tolerability. PCSK9 inhibitors are effective and safe in both sexes, in pediatric patients as well as in the elderly. Initiation of PCSK9 mAb during acute myocardial infarction is safe and leads to beneficial morphological plaque changes. The PCSK9 inhibitors evolocumab, alirocumab and inclisiran lower LDL-C in patients with heterozygous familial hypercholesterolemia (FH), while the response of patients with homozygous FH is heterogeneous. New areas of application beyond lipid lowering are currently investigated.Summary: PCSK9 inhibitors are safe, well tolerated, and effective in primary and secondary prevention in a wide range of patient populations.","PeriodicalId":11109,"journal":{"name":"Current opinion in lipidology","volume":null,"pages":null},"PeriodicalIF":3.8000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in lipidology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MOL.0000000000000935","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Monoclonal antibodies (mAb) targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) have been established in cardiovascular risk prevention. The purpose of this review is to summarize the effects of PCSK9 inhibitors across different patient populations.

Recent findings: Long-term data on the use of evolocumab and alirocumab shows persisting low- density lipoprotein cholesterol (LDL-C) lowering and good tolerability. PCSK9 inhibitors are effective and safe in both sexes, in pediatric patients as well as in the elderly. Initiation of PCSK9 mAb during acute myocardial infarction is safe and leads to beneficial morphological plaque changes. The PCSK9 inhibitors evolocumab, alirocumab and inclisiran lower LDL-C in patients with heterozygous familial hypercholesterolemia (FH), while the response of patients with homozygous FH is heterogeneous. New areas of application beyond lipid lowering are currently investigated.

Summary: PCSK9 inhibitors are safe, well tolerated, and effective in primary and secondary prevention in a wide range of patient populations.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

不同患者群体中的 9 型枯草蛋白酶/kexin 抑制剂。

综述目的：针对9型枯草蛋白酶/kexin（PCSK9）的单克隆抗体（mAb）已被确定用于心血管风险预防。本综述旨在总结 PCSK9 抑制剂在不同患者人群中的效果：关于使用 evolocumab 和 alirocumab 的长期数据显示，低密度脂蛋白胆固醇（LDL-C）持续降低，且耐受性良好。PCSK9抑制剂对男女、儿童和老年人都有效且安全。在急性心肌梗死期间开始使用 PCSK9 mAb 是安全的，并能带来有益的斑块形态变化。PCSK9抑制剂evolocumab、alirocumab和inclisiran可降低杂合子家族性高胆固醇血症（FH）患者的低密度脂蛋白胆固醇，而同合子FH患者的反应则不尽相同。总结：PCSK9 抑制剂安全、耐受性好，在各种患者人群的一级和二级预防中均有效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current opinion in lipidology 医学-内分泌学与代谢

CiteScore

6.70

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： With its easy-to-digest reviews on important advances in world literature, Current Opinion in Lipidology offers expert evaluation on a wide range of topics from six key disciplines including nutrition and metabolism, genetics and molecular biology, and hyperlipidaemia and cardiovascular disease. Published bimonthly, each issue covers in detail the most pertinent advances in these fields from the previous year. This is supplemented by a section of Bimonthly Updates, which deliver an insight into new developments at the cutting edge of the disciplines covered in the journal.